Thelansis’s "Epilepsy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Epilepsy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Epilepsy is a chronic neurological disorder defined by a predisposition to recurrent unprovoked seizures, resulting from abnormal excessive or synchronous neuronal activity arising from diverse structural, genetic, metabolic, infectious, immune, and unknown aetiologies, classified by the ILAE framework into focal, generalised, combined, and unknown onset seizure types. Underlying mechanisms encompass disrupted excitatory-inhibitory neurotransmitter balance, ion channel dysfunction, synaptic plasticity abnormalities, and network-level hyperexcitability; genetic epilepsies including Dravet syndrome and KCNQ2-related epilepsy represent increasingly recognised and therapeutically relevant molecular entities. Patients present with stereotyped paroxysmal events including convulsions, absence episodes, focal awareness impairment, and automatisms, with diagnosis requiring at least two unprovoked seizures or one seizure with high recurrence risk. Diagnostic workup integrates EEG characterising epileptiform activity and seizure semiology, MRI identifying structural aetiologies, and genetic panel testing in suspected hereditary epilepsies. Antiseizure medications remain the therapeutic cornerstone; levetiracetam, lamotrigine, and valproate are widely utilised first-line agents, with lacosamide, brivaracetam, and cenobamate representing modern options with favourable efficacy and tolerability profiles. Cenobamate has demonstrated particularly compelling seizure freedom rates in focal epilepsy. Cannabidiol is approved for Dravet syndrome and Lennox-Gastaut syndrome. Surgical resection, vagus nerve stimulation, responsive neurostimulation, and deep brain stimulation address drug-resistant epilepsy. Fenfluramine is approved for Dravet syndrome seizure reduction. Prognosis is favourable in two-thirds of patients achieving seizure control; driving restrictions, SUDEP risk counselling, psychosocial support, and patient-centred shared decision-making are integral to comprehensive long-term management.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Epilepsy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report
Our team will get in touch with you shortly about the Epilepsy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035 report.